Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
Colorectal Cancer Metastatic
DRUG: Based on sensitivity analysis
Progression free survival 8 weeks after start of treatment, 42-63 days after start of treatment
Progression free survival, Every 8 weeks until progression or death up to 2.5 years|Overall survival, Every 3 months up to 2.5 years|Response rate, Every 8 weeks until progression up to 2.5 years|Quality of life as measured by questionnaire EQ-5D-5L, Every 8 weeks up to 2.5 years
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.